| 1 | |
|----|---|
| 2 | |
| 3 | |
| 4 | ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) |
| 5 | FOR |
| 6 | CARBONYL SULFIDE |
| 7 | (CAS Reg. No. 463-58-1) |
| 8 | |
| 9 | O=C=S |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | INTERIM |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |

| 1 | |
|----|--|
| 2 | ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) |
| 3 | FOR |
| 4 | CARBONYL SULFIDE |
| | |
| 5 | (CAS Reg. No. 463-58-1) |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | INTERIM |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |

1 PREFACE 2 3 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, 4 the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 5 (NAC/AEGL Committee) has been established to identify, review and interpret relevant 6 toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 7 8 AEGLs represent threshold exposure limits for the general public and are applicable to 9 emergency exposure periods ranging from 10 minutes to 8 hours. Three levels – AEGL-1, 10 AEGL-2 and AEGL-3 — are developed for each of five exposure periods (10 and 30 minutes, 1 11 hour, 4 hours, and 8 hours) and are distinguished by varying degrees of severity of toxic effects. 12 The three AEGLs are defined as follows: 13 14 AEGL-1 is the airborne concentration (expressed as parts per million or milligrams per 15 cubic meter [ppm or mg/m^3]) of a substance above which it is predicted that the general 16 population, including susceptible individuals, could experience notable discomfort, irritation, or 17 certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient 18 and reversible upon cessation of exposure. 19 20 AEGL-2 is the airborne concentration (expressed as ppm or mg/m^3) of a substance above 21 which it is predicted that the general population, including susceptible individuals, could 22 experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to 23 escape. 24 AEGL-3 is the airborne concentration (expressed as ppm or mg/m^3) of a substance above 25 26 which it is predicted that the general population, including susceptible individuals, could 27 experience life-threatening health effects or death. 28 29 Airborne concentrations below the AEGL-1 represent exposure levels that could produce 30 mild and progressively increasing but transient and nondisabling odor, taste, and sensory irritation 31 or certain asymptomatic, non-sensory effects. With increasing airborne concentrations above each 32 AEGL, there is a progressive increase in the likelihood of occurrence and the severity of effects 33 described for each corresponding AEGL. Although the AEGL values represent threshold levels 34 for the general public, including susceptible subpopulations, such as infants, children, the elderly, 35 persons with asthma, and those with other illnesses, it is recognized that individuals, subject to 36 unique or idiosyncratic responses, could experience the effects described at concentrations below 37 the corresponding AEGL 38 39

| 1 | TABLE OF CONTENTS | |
|--|--|--|
| 2 | PREFACE | |
| 3 | LIST OF TABLES | 6 |
| 4 | 1. INTRODUCTION | 9 |
| 5 | 2. HUMAN TOXICITY DATA | 9 |
| 6 7 8 9 10 11 12 | ANIMAL TOXICITY DATA | 10 14 16 17 17 |
| 13 14 15 16 17 18 19 20 | 4. SPECIAL CONSIDERATIONS 4.1. Metabolism and Disposition 4.2. Mechanism of Toxicity 4.3. Structure Activity Relationships. 4.4. Other Relevant Information 4.4.1. Species Variability 4.4.2. Susceptible Populations 4.4.3. Time Scaling | 17 17 17 17 18 18 18 18 18 18 18 |
| 21 22 23 24 25 26 27 28 | DATA ANALYSIS FOR AEGL-1 | 18 18 18 18 18 18 19 19 19 19 |
| 28 29 30 31 32 33 34 35 | 6.3. Derivation of AEGL-2 7. DATA ANALYSIS FOR AEGL-3 | 20 20 20 20 20 20 20 21 21 |
| 36 37 | 8.2. Comparison with Other Standards and Guidennes | |
| 21 | | |

| 1 | APPENDIX A: DERIVATION OF AEGL VALUES | 23 |
|--------|--|----|
| 2 | APPENDIX B: DERIVATION SUMMARY FOR CARBONYL SULFIDE AEGLS | 27 |
| 3 | APPENDIX C: CATEGORY PLOT FOR CARBONYL SULFIDE | 32 |
| 4 5 | APPENDIX D: BENCHMARK DOSE CALCULATIONS FOR CARBONYL SULFIDE | 34 |

| 1 | LIST OF TABLES | |
|----|---|----|
| 2 | | |
| 3 | TABLE 1. Summary of AEGL Values for Carbonyl Sulfide | 8 |
| 4 | TABLE 2. Chemical and Physical Properties | 9 |
| 5 | TABLE 3. Mortality in rats exposed to carbonyl sulfide for 4-hours* | 11 |
| 6 | TABLE 4. Clinical signs observed during exposure in rats exposed to carbonyl sulfide for 4-hours (incidence/6 | |
| 7 | animals/sex) | 12 |
| 8 | TABLE 5. Clinical signs observed immediately post-exposure in rats exposed to carbonyl sulfide for 4-hours | |
| 9 | (incidence) | 12 |
| 10 | TABLE 6. Mortality in rats exposed to carbonyl sulfide for 4-hours | 12 |
| 11 | TABLE 7. Acute inhalation toxicity of carbonyl sulfide in rats (time saturation test) | 14 |
| 12 | TABLE 8. Acute inhalation toxicity of carbonyl sulfide in cats, rabbits, and guinea pigs | 14 |
| 13 | TABLE 9. AEGL-1 Values for Carbonyl Sulfide | 19 |
| 14 | TABLE 10. AEGL-2 Values for Carbonyl Sulfide | 20 |
| 15 | TABLE 11. AEGL-3 Values for Carbonyl Sulfide | 21 |
| 16 | TABLE 12. Summary of AEGL Values | 21 |
| | | |

2

SUMMARY

3 Carbonyl sulfide is a colorless gas. Pure carbonyl sulfide is odorless; however, commercial 4 carbonyl sulfide has a typical sulfur odor. It is produced naturally in soil, marshes, roots and 5 shoots of plants, manure, compost, and by microorganisms. It is found in cheese, horseradish, and 6 brassica vegetables. The natural occurrence of carbonyl sulfide is associated with the occurrence 7 of carbon disulfide and the environmental sulfur cycle (Bartholomaeus and Haritos, 2005). Up to 8 45 ppm carbonyl sulfide has been reported in mainstream tobacco smoke (Bartholomaeus and 9 Haritos, 2005). It is used as an intermediate in the synthesis of thio-organic compounds and as an 10 intermediate in the production of thiocarbamate herbicides and aliphatic polyureas, and has 11 recently been introduced as a new grain fumigant which has been developed to replace methyl 12 bromide. Carbonyl sulfide, similar to hydrogen sulfide, causes respiratory paralysis. However, the 13 odor warning properties are not as prominent as those of hydrogen sulfide. Carbonyl sulfide also 14 causes neurotoxicity. 15

Carbonyl sulfide has poor warning properties; it may cause serious effects or lethality at
 concentrations causing no signs or symptoms. Data were insufficient for deriving AEGL-1 values
 for carbonyl sulfide. Therefore, AEGL-1 values are not recommended.

20 A NOEL for clinical signs and brain pathology (300 ppm) in rats exposed to carbonyl 21 sulfide for 6-hours (Morgan et al., 2004) was used as the POD for AEGL-2 values. (Animals 22 exposed to the next highest concentration tested, 600 ppm, exhibited severe clinical signs and brain pathology). Values were scaled across time using the $C^n x t = k$ equation, where n = 3 when 23 24 extrapolating to shorter time points and n = 1 when extrapolating to longer time points in order to 25 derive values protective of human health (NRC, 2001). The 30-min AEGL-2 value was adopted as 26 the 10-min AEGL-2 value because of the added uncertainty of extrapolating from the 6-hour POD 27 to 10-min. An intraspecies uncertainty factor (UF) of 3 was applied and is considered sufficient 28 due to the steep concentration-response curve, which implies limited intra-individual variability. 29 The steep curve is evidenced in several studies. No mortality was noted in rats exposed to 943 30 ppm carbonyl sulfide for 4-hours, and 4/10 rats died at 1090 ppm and 10/10 rats died when 31 exposed to 1210 ppm (DuPont, 1981). In another 4-hour rat study (Monsanto, 1985a), no 32 mortality was noted at 993 ppm; whereas, 4/12 rats died at 1060 ppm, and 11/12 rats died at 1147 33 ppm. Thiess et al. (1968) observed no mortality in rats exposed to 1000 ppm for 75-min and death of 3/6 rats exposed to 1000 ppm for 90-min. An interspecies UF of 3 was also applied. Although 34 35 the animal data suggest some species variability and the rat is not the most sensitive species [mortality incidences for animals exposed to 1000 ppm carbonyl sulfide for 90 minutes were as 36 37 follows: 0/6 for guinea pigs, 3/6 for rats, 8/14 for rabbits, and 6/6 for cats (Thiess et al., 1968)], use 38 of the full default interspecies UF of 10 would yield AEGL-2 values that are inconsistent with the 39 overall database. [AEGL-2 values derived using a total UF of 30 would be 23 ppm for 10- and 30-40 min, 18 ppm for 1-hr, 11 ppm for 4-hr, and 7.7 ppm for 8-hr; no treatment-related effects were noted in rats exposed to 51 ppm 6-hr/day for 11 days (Monsanto, 1985b), or 75, 150, or 300 ppm 41 42 6-hr/day for 4 days (Morgan et al., 2004)]. Therefore, the total adjustment is 10.

43

44 A 4-hour rat BMCL₀₅ and BMC₀₁ (both calculated values are equivalent) of 952 ppm 45 (Monsanto, 1985a) was used as the point-of-departure (POD) for AEGL-3 values. Values were 46 scaled across time using the $C^n x t = k$ equation, where n = 3 when extrapolating to shorter time 47 points and n = 1 when extrapolating to longer time points in order to derive values protective of 48 human health (NRC, 2001). The 30-min AEGL-3 value was adopted as the 10-min AEGL-3 value 49 because of the added uncertainty of extrapolating from the 4-hour POD to 10-min. An intraspecies

- 1 uncertainty factor (UF) of 3 was applied and is considered sufficient due to the steep
- 2 concentration-response curve, which implies limited intra-individual variability. The steep curve
- 3 is evidenced in several studies. No mortality was noted in rats exposed to 943 ppm carbonyl
- 4 sulfide for 4-hours, and 4/10 rats died at 1090 ppm and 10/10 rats died when exposed to 1210 ppm
- (DuPont, 1981). In another 4-hour rat study (Monsanto, 1985a), no mortality was noted at 993 5
- 6 ppm; whereas, 4/12 rats died at 1060 ppm, and 11/12 rats died at 1147 ppm. Thiess et al. (1968) 7 observed no mortality in rats exposed to 1000 ppm for 75-min and death of 3/6 rats exposed to
- 8 1000 ppm for 90-min. An interspecies UF of 3 was also applied. Although the animal data suggest
- 9 some species variability and the rat is not the most sensitive species [mortality incidences for
- 10 animals exposed to 1000 ppm carbonyl sulfide for 90 minutes were as follows: 0/6 for guinea pigs,
- 11 3/6 for rats, 8/14 for rabbits, and 6/6 for cats (Thiess et al., 1968)], use of the full default
- 12 interspecies UF of 10 would yield AEGL-3 values that are inconsistent with the overall database.
- 13 [AEGL-3 values derived using a total UF of 30 would be 63 ppm for 10- and 30-min, 50 ppm for
- 14 1-hr, 32 ppm for 4-hr, and 16 ppm for 8-hr; no treatment-related effects were noted in rats exposed
- to 51 ppm 6-hr/day for 11 days (Monsanto, 1985b), or 75, 150, or 300 ppm 6-hr/day for 4 days 15
- 16 (Morgan et al., 2004). No mortality or clinical signs were present in rats exposed to 200, 300, or

17 400 ppm 6 hr/day, 5 days/week for 12-weeks; however, significant decreases in brain

18 cholinesterase activity were noted at all three concentrations (Morgan et al., 2004)]. Therefore, the

- 19 total adjustment is 10.
- 20 21
- 22

The calculated values are listed in the table below.

| | TABLE 1. Summary of AEGL Values for Carbonyl Sulfide | | | | | | | | | | | |
|--------------------------|--|-------------------------------------|-------------------------------------|------------------------------------|---------------------------------|---|--|--|--|--|--|--|
| Classification | 10-mim | 30-min | 1-h | 4-h | 8-h | Endpoint (Reference) | | | | | | |
| AEGL-1 (Nondisabling) | NR | NR | NR | NR | NR | | | | | | | |
| AEGL-2 (Disabling) | 69 ppm (170 mg/m ³) | 69 ppm (170 mg/m ³) | 55 ppm (130 mg/m ³) | 34 ppm (83 mg/m ³) | 23 ppm (56 mg/m ³) | NOEL for clinical signs and brain pathology in rats (Morgan et al., 2004) | | | | | | |
| AEGL-3 (Lethal) | 190 ppm (470 mg/m ³) | 190 ppm (470 mg/m ³) | 150 ppm (370 mg/m ³) | 95 ppm (230 mg/m ³) | 11 | 4-hour rat BMCL ₀₅ /BMC ₀₁ (Monsanto, 1985a) | | | | | | |

23 24 NR: Not Recommended due to insufficient data. The absence of AEGL-1 values does not imply that concentrations

below AEGL-2 are without effect. Carbonyl sulfide has poor warning properties; it may cause serious effects or

25 lethality at concentrations causing no signs or symptoms

1. INTRODUCTION

3 Carbonyl sulfide is a colorless gas. Pure carbonyl sulfide is odorless; however, commercial 4 carbonyl sulfide has a typical sulfur odor. It may be made by the reaction of dilute sulfuric acid 5 with ammonium thiocyanate, hydrolysis of ammonium or potassium thiocyanate, by the reaction 6 of carbon monoxide with sulfur, reduction of sulfur dioxide with carbon, or hydrolysis of carbon 7 disulfide (HSDB, 2007). Carbonyl sulfide is produced naturally in soil, marshes, roots and shoots 8 of plants, manure, compost, and by microorganisms. It is found in cheese, horseradish, and 9 brassica vegetables. The natural occurrence of carbonyl sulfide is associated with the occurrence 10 of carbon disulfide and the environmental sulfur cycle (Bartholomaeus and Haritos, 2005). Up to 11 45 ppm carbonyl sulfide has been reported in mainstream tobacco smoke (Bartholomaeus and 12 Haritos, 2005). It is used as an intermediate in the synthesis of thio-organic compounds and as an 13 intermediate in the production of thiocarbamate herbicides and aliphatic polyureas. Carbonyl 14 sulfide has recently been introduced as a new grain fumigant which has been developed to replace methyl bromide (being phased out) and to supplement phosphine gas (experiencing increased 15 16 insect resistance). Fumigation of grain products with carbonyl sulfide results in residues that are 17 near to or indistinguishable from natural background levels (HSDB, 2007). Carbonyl sulfide, similar to hydrogen sulfide, causes respiratory paralysis. Carbonyl sulfide also causes 18 19 neurotoxicity. The warning properties of carbonyl sulfide are not as prominent as those of 20 hydrogen sulfide. Carbonyl sulfide has poor warning properties; it may cause serious effects or 21 lethality at concentrations causing no signs or symptoms (HSDB, 2007). Chemical and physical properties are listed in Table 2.

22 p 23

1

2

| TABLE 2. Chemical and Physical Properties | | | | | | | | |
|---|--|------------|--|--|--|--|--|--|
| Parameter | Value | References | | | | | | |
| Synonyms | Carbon monoxide monosulfide; carbon oxide sulfide; carbonoxysulfide; oxycarbon sulfide | HSDB, 2007 | | | | | | |
| Chemical formula | COS | HSDB, 2007 | | | | | | |
| Molecular weight | 60.1 | HSDB, 2007 | | | | | | |
| CAS Reg. No. | 463-58-1 | HSDB, 2007 | | | | | | |
| Physical state | Colorless gas | HSDB, 2007 | | | | | | |
| Solubility in water | 1220 mg/L at 25 °C; may hydrolyze to carbon dioxide and hydrogen sulfide | HSDB, 2007 | | | | | | |
| Vapor pressure | 9412 mm Hg at 25 °C | HSDB, 2007 | | | | | | |
| Vapor density | 2.1 (air = 1) | HSDB, 2007 | | | | | | |
| Density/Specific Gravity | 1.028 g/L at 17 °C | HSDB, 2007 | | | | | | |
| Melting point | -138.8 °C | HSDB, 2007 | | | | | | |
| Boiling point | -50 °C | HSDB, 2007 | | | | | | |
| Flammable range | 12-28% (600-1000 °F) | HSDB, 2007 | | | | | | |
| Conversion factors | 1 ppm = 2.45 mg/m^3 1 mg/m ³ = 0.41 ppm | | | | | | | |

24 25

26

27

2. HUMAN TOXICITY DATA

Thiess et al. (1968) reported a case study of two workers exposed to carbonyl sulfide in the cellar (6 square meters x 1.6 meters deep) of a "production plant." The workers, ages 56 (mechanic) and 24 years, were exchanging part of a dye pipe. The 56-year old suddenly became very dizzy without noticing any odor. He immediately ran to the staircase and his co-worker

32 followed. He became "really tired" and noticed that he "couldn't really breathe anymore."

1 Everything was "dancing in front of his eyes" and he collapsed in front of the cellar entrance.

2 When he regained consciousness, he could not immediately remember what had happened. He

found the co-worker unconscious and tried to carry him out. However, he again became dizzy and

felt a "dull pressure" in his head and chest. He ran back to the escape route and became
unconscious for a second time. When he regained consciousness, he was able to call for help. He

5 unconscious for a second time. When he regained consciousness, he was able to call for help. He 6 was administered oxygen and taken to the hospital fully conscious; on admission, the lungs and

was administered oxygen and taken to the hospital fully conscious, on admission, the fully and
 heart were clinically and radiologically normal. He experienced headaches for 3 days and was

8 discharged on day 4. The 24-year old worker was found dead. Autopsy showed dark brown-red

9 colored blood, lungs filled with blood, blue-red colored kidneys, and moderate brain swelling and 10 edema. No carbonyl sulfide concentration was reported.

11

12 Kilburn and Warshaw (1995) reported abnormal neurobehavioral function (two-choice 13 reaction time, balance, color discrimination, digit symbol, immediate recall of a story) in former 14 workers and neighbors living downwind from a coal refinery. Subjects also complained of headaches, nausea, vomiting, depression, personality changes, nose bleeds, and breathing 15 16 problems. Monitoring outside the desulfurization unit showed 24-hour average concentrations of 17 0.1 to 21.1 ppm mercaptans, 0 to 8.8 ppm hydrogen sulfide, 2.6 to 51.1 ppm carbonyl sulfide, and 6.1 to 70.7 ppm total reduced sulfur gases. The authors attributed the observed effects to exposure 18 19 to reduced sulfur gases; however, worker exposures were not monitored.

20 21

22

An odor threshold of 0.1 ppm has been reported (U.S. EPA, 1992).

23 **3.** ANIMAL TOXICITY DATA

24 **3.1.** Acute Toxicity25

26 Groups of ten male Crl:CD rats were exposed to 477, 943, 981, 1050, 1090, 1160, 1210, 27 1270, or 2180 ppm (analytical concentrations) carbonyl sulfide for 4 hours, followed by a 14-day 28 observation period (DuPont, 1981). The whole-body exposure chambers were constructed of glass 29 and had an internal volume of 20 L. The test atmosphere was generated by metering carbonyl 30 sulfide (as a pressurized gas) through Teflon lines into a mixing flask where dilution air and 31 oxygen were added. The atmosphere was then introduced into the top of the exposure chamber 32 with total airflow of 10 L/min. The test atmospheres were analyzed at half-hour intervals during 33 each exposure by gas chromatography. Clinical signs increased with increasing carbonyl sulfide concentration. Signs observed during exposure (exposure groups not specified) included labored 34 35 breathing, decreased or no response to sound, lack of coordination, convulsions, pallor, head bobbing, and uncontrolled body movements. Signs noted during the observation period included 36 37 rapid breathing, pallor, hair loss, cloudy eyes, diarrhea, wet perineal area, lethargy, red ocular 38 discharge, stained nose and mouth, partially closed eyes, lack of righting reflex, and slight to 39 severe weight loss. Animals in the 943 ppm group showed slight to moderate weight loss at 1-2 40 days post-exposure, followed by normal weight gain. At 981 ppm and above, slight to severe weight loss was noted 1-8 days post-exposure. No other specifics concerning clinical signs were 41 42 described. A 4-hour LC₅₀ value of 1111 ppm (95% CI = 1058-1158 ppm), BMCL₀₅ of 969 ppm, and BMC₀₁ of 992 ppm were calculated. These calculations included the animal sacrificed in 43 44 extremis at 981 ppm. Mortality data are summarized in Table 3.

| | TABLE 3. Mortality in rats exposed to carbonyl sulfide for 4-hours* | | | | | | | | | | |
|---------------------------|---|---|--|--|--|--|--|--|--|--|--|
| Concentration | Mortality | | | | | | | | | | |
| Concentration | # Deaths/# Exposed | Time of Death | | | | | | | | | |
| $477 \pm 21 \text{ ppm}$ | 0/10 | - | | | | | | | | | |
| $943 \pm 26 \text{ ppm}$ | 0/10 | - | | | | | | | | | |
| 981 ± 89 ppm | 1/10 | Sacrificed in extremis (day not given) | | | | | | | | | |
| $1050 \pm 22 \text{ ppm}$ | 0/10 | - | | | | | | | | | |
| $1090 \pm 23 \text{ ppm}$ | 4/10 | 2 during exposure; 1 on day 8; 1 on day 9 | | | | | | | | | |
| | | | | | | | | | | | |
| $1160 \pm 32 \text{ ppm}$ | 5/10 | 1 during exposure; 1 on day 1; 3 on day 9 | | | | | | | | | |
| $1210 \pm 24 \text{ ppm}$ | 10/10 | 3 during exposure; 5 on day 1; 1 on day 7; 1 on day 8 | | | | | | | | | |
| $1270 \pm 76 \text{ ppm}$ | 10/10 | 9 during exposure; 1 on day 1 | | | | | | | | | |
| $2180 \pm 66 \text{ ppm}$ | 10/10 | 10 during exposure | | | | | | | | | |
| | | | | | | | | | | | |
| LC ₅₀ | 1111 ppm | | | | | | | | | | |
| BMC ₀₁ | 992 ppm | | | | | | | | | | |
| BMCL ₀₅ | 969 ppm | | | | | | | | | | |

2 *DuPont, 1981

3

4 In another study, groups of six male and six female Sprague-Dawley rats were exposed to 5 0, 804, 993, 1062, 1096, 1147, or 1189 ppm (analytical concentrations) carbonyl sulfide for 4 6 hours, followed by a 14-day observation period (Monsanto, 1985a). The whole-body exposure 7 chamber was a 0.3 m³ Rochester-type stainless steel chamber with a pyramidal top and bottom and 8 a glass window in the door. The test atmosphere was generated by drawing conditioned room air 9 through the chamber at a rate of approximately 50 L/min and metering the carbonyl sulfide gas (by 10 a pressure regulator, needle valve, and rotometer) directly into the chamber inlet. The carbonyl sulfide concentration in the test atmosphere was monitored by infrared analysis continuously 11 12 during the exposure periods and recorded at hourly intervals. Clinical signs noted during exposure 13 are presented in Table 4, and signs noted immediately after exposure are presented in Table 5. 14 Animals surviving longer than 24-hours post-exposure exhibited few clinical signs; the most 15 prominent was circling. Circling was noted in approximately half of the surviving animals in the 16 1062 ppm group during the first four days post-exposure; whereas, circling was observed in only 17 one of this group between days 5-7 post-exposure. Four-hour LC₅₀ values of 1082 ppm (95% CI = 18 1059-1102 ppm), 1094 ppm (95% CI = 1055-1136 ppm), and 1070 ppm (95% CI = 1022-1100 19 ppm) were calculated for both sexes combined, males, and females, respectively. A BMCL₀₅ of 20 951.9 ppm and BMC $_{01}$ of 951.7 ppm were calculated. Mortality data are summarized in Table 6. 21

CARBONYL SULFIDE

INTERIM: 05-2008/ Page 12 of 38

| TABLE 4. Clinical signs observed during exposure in rats exposed to carbonyl sulfide for 4-hours (incidence/6 animals/sex) | | | | | | | | | | | | | | | | |
|--|------------|---|--------|---|--------------|---|----------|---|-------------------------|---|-------------------|---|-------------|---|---------------------------|---|
| Concentration | Convulsion | | Tremor | | Hypoactivity | | Cyanosis | | Breathing difficulty | | Nasal bleeding | | Lacrimation | | Behavioral abnormality | |
| | Μ | F | Μ | F | Μ | F | Μ | F | Μ | F | Μ | F | Μ | F | Μ | F |
| 0 ppm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 804 ppm | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 993 ppm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1062 ppm | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 1 | 4 |
| 1096 ppm | 2 | 1 | 2 | 0 | 6 | 6 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 |
| 1147 ppm | 2 | 4 | 2 | 0 | 6 | 6 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 6 | 6 |
| 1189 ppm | 1 | 1 | 0 | 0 | 6 | 6 | 0 | 0 | 6 | 6 | 0 | 0 | 6 | 6 | 0 | 0 |

Monsanto, 1985a

1

| Concentration | Convu | Ilsion | Tremor | | Hypoactivity | | Cyanosis | | Breathing difficulty | | Chromadacryorrhea | | Salivation/ Lacrimation | |
|---------------|-------|--------|--------|-----|--------------|-----|----------|-----|-------------------------|-----|-------------------|-----|----------------------------|-----|
| | Μ | F | М | F | Μ | F | М | F | Μ | F | М | F | Μ | F |
| 0 ppm | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| 804 ppm | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| 993 ppm | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| 1062 ppm | 0/6 | 1/5 | 1/6 | 1/5 | 1/6 | 2/5 | 0/6 | 1/5 | 0/6 | 1/5 | 2/6 | 0/5 | 0/6 | 1/5 |
| 1096 ppm | 0/3 | 1/4 | 0/3 | 0/4 | 1/3 | 1/4 | 0/3 | 0/4 | 0/3 | 1/4 | 0/3 | 1/4 | 0/3 | 1/4 |
| 1147 ppm | 0/5 | 1/2 | 0/5 | 1/2 | 5/5 | 2/2 | 3/5 | 2/2 | 2/5 | 0/2 | 0/5 | 0/2 | 1/5 | 1/2 |
| 1189 ppm | 0/1 | 2/3 | 0/1 | 1/3 | 1/1 | 3/3 | 0/1 | 1/3 | 0/1 | 2/3 | 1/1 | 0/3 | 1/1 | 1/3 |

2

| TABL | E 6. Mortality in rats expo | sed to carbonyl sulfide for 4- | -hours | | |
|--------------------|-----------------------------|--------------------------------|-----------|--|--|
| Concentration | | | | | |
| Concentration | Males | Females | Combined | | |
| 0 ppm | 0/6 | 0/6 | 0/12 | | |
| 804 ppm | 0/6 | 0/6 | 0/12 | | |
| 993 ppm | 0/6 | 0/6 | 0/12 | | |
| 1062 ppm | 1/6 | 3/6 | 4/12 | | |
| 1096 ppm | 4/6 | 4/6 | 8/12 | | |
| 1147 ppm | 5/6 | 6/6 | 11/12 | | |
| 1189 ppm | 6/6 | 5/6 | 11/12 | | |
| LC ₅₀ | 1094 ppm | 1070 ppm | 1082 ppm | | |
| BMC ₀₁ | ** | | 951.7 ppm | | |
| BMCL ₀₅ | | | 951.9 ppm | | |

Monsanto, 1985a

3 4

5 Morgan et al. (2004), exposed groups of five male F344 rats to 0, 75, 150, 300, or 600 ppm 6 carbonyl sulfide for 6-hours, followed by a 2-week follow-up period. Animals were exposed in 7 Hazleton 2000 exposure chambers with an airflow of 400 L/min. Carbonyl sulfide concentrations 8 in the test atmospheres were analytically determined by gas chromatography. No mortality occurred at any test concentration. Animals in the 600 ppm group were lethargic when observed 9 10 immediately after exposure and the following morning (day 2). By the afternoon of day 2, clinical signs in the 600 ppm group included hypothermia, lethargy, head tilt, and ataxia. The clinical 11 condition improved during the 14-day follow-up; however, several rats continued to exhibit ataxia 12 13 with head tilt. At necropsy, micropsopic evaluation of brain sections from rats in the 600 ppm group showed necrosis and microgliosis in the cerebellar roof nucleus, internal capsule, and 14 thalamus. Vacuolation of the cerebellar medullary white matter and fifth cranial nerve tract were 15

also noted. No clinical signs or brain lesions were reported in rats in the 0, 75, 150, or 300 ppm
 groups. Therefore, 75 and 150 ppm are considered no-effect-levels for all effects, and 300 ppm is
 a no-effect-level for clinical signs and brain pathology.

5 In another set of experiments, Thiess et al. (1968), generated carbonyl sulfide from 6 potassium cyanide and dilute sulfuric acid for acute inhalation toxicity tests on rats, cats, rabbits, 7 and guinea pigs. Fresh carbonyl sulfide was produced every 24 hours, and some exposure 8 concentrations were measured via an infrared spectrophotometer.

10 Clinical signs in rats were described as severe tonic-clonic "cramps." When rats were 11 removed from the test atmosphere immediately at the onset of convulsions (and allowed to breathe 12 clean air), no mortality was noted. Gross examination of deceased rats showed no treatment-13 related effects. When rats were examined immediately after death, heart function was "still 14 present." Therefore, the authors suggested that death was due to respiratory paralysis.

16 Clinical signs observed in cats included salivation, followed by respiratory problems, 17 balancing problems, prostration, nausea, and fecal discharge. After exposure for 1-hour, tonic-18 clonic cramps were noted, followed by shortness of breath and respiratory paralysis. Four cats 19 died during exposure and two died within 24-hours post-exposure. No clinical signs were noted in 20 cats exposed to 300 ppm for 6 hours. Insignificant lung edema was noted in 4/6 cats that died. 21

Clinical signs in rabbits also included clonic-tonic cramps. Most rabbits died within one hour or several hours after exposure; however, three delayed deaths occurred after 7-18 days. Surviving rabbits quickly recovered after the exposure period. Approximately one-half of the decedent animals showed insignificant lung edema; no abnormalities were noted in the three rats with delayed deaths.

27

9

No mortality or clinical signs occurred in guinea pigs. Rat data are summarized in Table 7,
and cat, rabbit, and guinea pig data are summarized in Table 8.

| TABLE 7. Acute inhalation toxicity of carbonyl sulfide in rats (time saturation test) | | | | | | | | | | | |
|---|----------------|----------------------|---|------------------------|---------------|--|--|--|--|--|--|
| Concer | ntration (ppm) | Exposure duration | Occurrence of tonic-clonic cramps | Mortality incidence | Time to death | | | | | | |
| Nominal | Analytical | | | | | | | | | | |
| 250,000 | - | 30 sec | 15 sec | 6/6 | 30 sec | | | | | | |
| 50,000 | - | 13 sec | 13 sec | 5/6 | 1 min | | | | | | |
| 10,000 | 8,000 | 4 min, 30 sec | 2 min, 20 sec | 6/6 | 4 min, 30 sec | | | | | | |
| 10,000 | - | 3 min | 1 min, 15 sec | 6/6 | 3 min | | | | | | |
| 10,000 | - | 1 min, 15 sec | 1 min, 15 sec | 0/6 | - | | | | | | |
| 3,000 | - | 9 min | 5 min, 30 sec | 3/6 | 8-14 min | | | | | | |
| 1,000 | - | 75 min | - | 0/6 | - | | | | | | |
| 1,000 | 1,400 | 90 min | 59 min | 3/6 | 75 min | | | | | | |

Theiss et al., (1968)

1 2

| TABLE 8. Acute inhalation toxicity of carbonyl sulfide in cats, rabbits, and guinea pigs | | | | | | |
|--|-------------|-------------------|---------------------|---------|-------------|--|
| Concentra | ation (ppm) | Exposure duration | Mortality incidence | | nce | |
| Nominal | Analytical | | Cats | Rabbits | Guinea pigs | |
| 3,000 | - | 30 min | - | 4/4 | - | |
| 3,000 | - | 4 min | - | 1/4 | - | |
| 1,000 | - | 120 min | - | 2/4 | - | |
| 1,000 | - | 90 min | 4/4 | 8/12 | 0/4 | |
| 1,000 | 1,300 | 90 min | 2/2 | 0/2 | 0/2 | |
| 300 | 500 | 6 hr | 0/2 | 0/2 | 0/2 | |

Theiss et al., (1968)

Nutt et al. (1996) exposed groups of male and female F344 rats nose only to 250-1400 ppm carbonyl sulfide for up to 4-hours, followed by a two week observation period. No lethality was observed below 500 ppm. Time to death was 30-min to 60-min from the start of exposure at 1400 ppm, 2-3 hours at 1000 ppm, 3-4 hours at 750 ppm, and >4 hours at 590 ppm. Exposure to higher concentrations caused an excitation phase followed by a depressive phase with decreased heart rate and body temperature. Lung, liver, kidney, and GI tract were congested at 750-1000 ppm. Rats 11 12 surviving exposure to > 500 ppm had motor impairment accompanied by swelling of myelin 13 sheaths in the corpus callosum, cerebellum, and and pyramidal tract. Partial to complete resolution 14 of clinical signs occurred during the 14-day observation period. No further information was 15 available (abstract). 16

17 3.1.1. Repeated-exposure Studies

18

19

Female rabbits (White Danish country breed) were exposed to 0 (17 rabbits) or 50 ppm (mean 54 ppm \pm 13 ppm; 18 rabbits) carbonyl sulfide continuously for 7 weeks (Kamstrup and 20 21 Hugod, 1979; Hugod and Astrup, 1980; Hugod, 1981). Five days after the start of exposure, three carbonyl sulfide-exposed rabbits were found dead and two others showed signs of serious 22 23 neurological disorders. The dead animals were discarded, whereas the impaired animals were 24 sacrificed and included in the histopathological analysis. There were no gross or microscopic 25 treatment-related effects in the heart, lungs, aorta, or main arteries. Lung sections of exposed 26 rabbits showed no signs of irritation or edema (Kamstrup and Hugod, 1979), and there was no 27 effect on myocardial ultrastructure (Hugod, 1981; Hugod and Astrup, 1980).

CARBONYL SULFIDE

Male and female Sprague-Dawley rats (numbers not stated) were exposed to 0, 10, 60, or nalytical concentrations) carbonyl sulfide 6 hr/day, 5 days/week over a 14-week period (Reyna and Ribelin, 1987). There were no clinical signs during exposure and no effects on urinalysis, clinical chemistry, gross pathology, histopathology, or pupillary reflexes. Lymphopenia (no concentration-response) was noted in males in all exposure groups and in high-concentration females. No other details were provided.

8 Groups of 10 male and 10 female Sprague-Dawley rats were exposed to 0, 51, 151, 253, or 9 453 ppm (analytical concentrations) carbonyl sulfide 6-hr/day for 11 days in a 2 week period 10 (Monsanto, 1985b). No clinical signs were noted until the second week of exposure when 3 males 11 and 7 females in the 453 ppm group exhibited ataxia, head tilting, circling, prostration, arched 12 backs, tremors, loss of muscle control, convulsions, and bulging and dilated eyes. These animals 13 were sacrificed in extremis after the eighth day of exposure. Concentration-related increases (p≤0.01) of approximately 68%, 113%, and 175% in methemobgobin were noted in males and 14 15 females in the 151, 253, and 453 ppm groups, respectively. No treatment-related effects were 16 noted at 51 ppm.

17

18 In a range-finding study, Morgan et al. (2004) exposed groups five male F344 rats to 0, 75, 19 150, 300, or 600 ppm carbonyl sulfide, 6 hours/day for 4 days. The exposure methods were similar to those described in the 6-hour study (Morgan et al., 2004) in section 3.1.1. No mortality, 20 21 morbidity, or clinical signs of toxicity were noted in rats exposed to 75, 150, or 300 ppm carbonyl 22 sulfide for 4 days. However, some (number not specified) rats in the 600 ppm group were 23 euthanized in a moribund condition after 2 days of exposure. Rats in the 600 ppm group showed 24 clinical signs of hypothermia, lethargy, ataxia, and impaired righting reflex. No microscopic brain 25 lesions were noted in rats exposed to 75, 150, or 300 ppm for 4 days. Microscopic evaluation of brain sections from moribund animals exposed to 600 ppm for 2 days showed extensive bilateral 26 symmetrical necrosis in parietal cortex area 1 and thalamus. Necrosis was also observed in the 27 28 retrosplenial granular cortex, ptriform cortex, red nucleus, cerebellar roof nucleus, posterior 29 collicular nucleus, and anterior olivary nucleus.

30

31 Based on the range-finding study, Morgan et al. (2004) conducted a two-week study. 32 Groups of ten male and ten female F344 rats were exposed to 0, 300, 400, or 500 ppm carbonyl 33 sulfide 6 hr/day, 5 days/week for 12 exposures over a two week period. The exposure methods were similar to those described in the 6-hour study (Morgan et al., 2004) in section 3.1.1. All ten 34 35 male and 4/10 female rats exposed to 500 ppm were euthanized in moribund condition and removed from the study. Male rats were found moribund after 4 (1/10), 5 (6/10), and 10 (3/10)36 37 exposures. Females were found moribund after 5 (2/10) and 11 (2/10) exposures. Moribund 38 animals showed signs of hypothermia, lethargy, ataxia with poor control of front and rear limbs. 39 Rats in the 300 and 400 ppm groups showed no adverse clinical signs. No treatment-related 40 effects on body weight were observed in of animals in the 300 and 400 ppm groups. In a functional operational battery (FOB), surviving females at 500 ppm had decreased forelimb and 41 42 hindlimb grip strength, hypotonia, and slight gait abnormalities. At 400 ppm, slight gait changes and hypotonia were noted in approximately half the rats. No clear FOB effects were noted at 300 43 44 ppm. Bilateral symmetrical malacia of the frontoparietal cortex was observed on gross brain 45 examination from rats exposed to 400 or 500 ppm. Microscopic brain lesions were noted in all early death rats exposed to 500 ppm and in 8/10 males and 9/10 females exposed to 400 ppm. 46 47 Brain lesions were noted only in one female in the 300 ppm group. Predominant lesions at 400 48 and 500 ppm included bilateral symmetrical necrosis in parietal cortex area 1 and putamen. At 500 49 ppm only, necrosis was observed in the retrosplenial cortex, thalamus, and posterior colliculus.

exposed to 500 ppm for 5 days.

1 anterior olivary nucleus, and vestibular nucleus. In animals exposed to 500 ppm for 12 days, there 2 was a loss of brain substance within the parietal cortex and retrosplenial cortex, compared to rats

2 3

4 5 Based on two-week study, Morgan et al. (2004) conducted a 12-week study. Groups of 6 twenty male and twenty female F344 rats were exposed to 0, 200, 300, or 400 ppm carbonyl 7 sulfide 6 hr/day, 5 days/week for up to 12 weeks. The exposure methods were similar to those 8 described in the 6-hour study (Morgan et al., 2004) in section 3.1.1. Interim sacrifices (5 9 rats/sex/concentration) were performed at 3 and 6 weeks to measure cytochrome C oxidase activity 10 in the brain. There were no treatment-related deaths, morbidity, clinical signs, or decrease in body 11 weight in animals of any exposure group. Decreases in clinical chemistry parameters were noted 12 in males; however, no concentration-response relationship was present and the findings were not 13 considered treatment-related or toxicologically significant. Mild FOB findings were not 14 concentration-related and were considered incidental to treatment. Concentration-related decreases (p<0.05 or p<0.001) in cytochrome C oxidase activity, ranging from 90% to 46% of 15 16 control, were noted the posterior colliculus and parietal cortex of males and females of all 17 treatment-groups at 3, 6, and 12 weeks. The decreases in cytochrome oxidase activity were present in rats exposed to 200 or 300 ppm in the absence of histopathological findings. At 12 18 19 weeks, microscopic brain lesions were noted only in male and female rats in the 400 ppm group. 20 Predominant lesions were unilateral and bilateral symmetrical cortical necrosis and cavitation in 21 the parietal cortex, and bilateral symmetrical neuronal loss with microgliosis and hemorrhage in 22 the posterior colliculus (Sills et al., 2004).

23 24

25

3.2. Developmental/Reproductive Toxicity

26 Groups twelve male albino rats were exposed to 0, 10, 60, or 182 ppm (analytical concentrations) carbonyl sulfide 6 hr/day, 5 days/week over a 13-week period (Reyna and Ribelin, 27 28 1987). These males were then mated with untreated females who were allowed to deliver and 29 wean a litter of pups. There were no clinical signs or body weight effects in exposed males. Only 30 12 of 24 females mated with 182 ppm males became pregnant, compared with 20 of 24 females in 31 the 0, 10, and 60 ppm groups. Reproductive behavior was not affected in the high-concentration 32 males. There were no effects on numbers of pups per litter, pup survival, and histopathology 33 (including reproductive tract). In a follow-up study, the treated males were allowed to recover for 10 weeks and were then mated with new females. There were no treatment-related effects on 34 35 mating and fertility indices or on gross and histopathology of reproductive organs. Groups of twelve female rats were then exposed to 0, 10, 60, or 180 ppm carbonyl sulfide 6 hr/day, 5 36 37 days/week over a 13-week period and mated with unexposed males. No treatment-related effects 38 were noted in dams or pups.

39

40 In a pilot teratology study, mated female rats were exposed to 0, 50, 149, 250, 348, or 451 (analytical concentrations) carbonyl sulfide from days 6-15 of gestation (Reyna and Ribelin, 41 42 1987). The only treatment-related clinical signs (respiratory problems and prostration) occurred in one 451 ppm female that died on day 14 of gestation. Decreased body weight gain was noted in 43 44 451 ppm animals throughout the treatment period and in the other treatment groups from days 10-45 13 of gestation. No treatment-related gross postmortem findings were noted, and there were no effects on total implantations, litter size, or resorptions. No gross fetal abnormalities were 46 47 observed. In the subsequent teratology study, mated female Sprague-Dawley rats were exposed to 48 0, 50, 200, or 400 ppm carbonyl sulfide from days 6-15 of gestation (Reyna and Ribelin, 1987). No maternal toicity was observed at 50 or 200 ppm; at 400 ppm, maternal death and decreased 49

1 body weight gain and food consumption were noted from days 6-16 of gestation. Pregnancy rate,

2 reproductive parameters, fetal body weight, and fetal sex distribution were comparable in all 3 groups. No further details were available.

3.3. Genotoxicity

7 Carbonyl sulfide was negative for *in vivo* spermatoctye chromosome aberrations in mice by 8 both oral and inhalation routes. It was also negative in oral and inhalation bone marrow 9 micronucleus assays in mice. Bacterial reverse mutation assays were generally negative. The exception was a weak positive response with and without metabolic activation in Salmonella 10 typhimurium strain TA98 only (Bartholomaeus and Haritos, 2005).

11 12 13

14 15

16

18

4 5

6

Chronic Toxicity/Carcinogenicity 3.4.

No data on chronic toxicity/carcinogenicity were located.

17 3.5. **Summary**

19 Acute inhalation toxicity studies in animals showed clinical signs consistent with 20 neurotoxicity and an extremely steep concentration-response curve. In repeated-exposure studies, 21 clinical signs of neurotoxicity were noted, often in the presence of concurrent histopathological 22 lesions in the brain. Carbonyl sulfide does not appear to be a developmental toxicant; however, 23 data in rats suggest that it may reversibly impair male fertility. Genotoxicity data were generally 24 negative, and no data on chronic toxicity/carcinogenicity were located. 25

26 4. SPECIAL CONSIDERATIONS

27 4.1. **Metabolism and Disposition**

28

29 The major metabolic pathway for carbonyl sulfide is conversion to hydrogen sulfide via 30 carbonic anhydrase (Chengelis and Neal, 1979). Using bovine erythrocyte carbonic anhydrase, the 31 conversion rate of carbonyl sulfide to hydrogen sulfide was shown to be rapid (Bartholomaeus and 32 Haritos, 2005). Chengelis and Neal (1980) showed that administration of the carbonic anhydrase 33 inhibitor, acetazolamide, protected against carbonyl sulfide toxicity in rats. The 1980 study also showed that the hydrogen sulfide metabolite is responsible for carbonyl sulfide toxicity. Rats pre-34 35 treated with sodium nitrite to induce 50% methemoglobinemia before carbonyl sulfide 36 administration, were protected from a dose of carbonyl sulfide that killed 75% of non pre-treated 37 rats. (Methemoglobin has been shown to bind sulfide and protect against hydrogen sulfide 38 toxicity). Also, the blood levels of hydrogen sulfide in rats treated with sodium sulfide in slight 39 excess of the LD₅₀ (to be comparable to the highest dose of carbonyl sulfide administered) were 40 comparable to levels seen with carbonyl sulfide. Therefore, approximate equally toxic doses of sodium sulfide and carbonyl sulfide resulted in similar blood concentrations of hydrogen sulfide. 41 42 43 Carbonyl sulfide is also a suicide substrate for cytochrome P450. It can be metabolized by

44

cytochrome P450 to produce carbon dioxide and a reactive sulfur species which binds to the heme 45 in the cytochrome P450 and results in inactivation (Bartholomaeus and Haritos, 2005).

- 46
- 47 4.2. **Mechanism of Toxicity**
- 48

It is thought that the hydrogen sulfide produced from the metabolism of carbonyl sulfide via carbonic anhydrase may be responsible for carbonyl sulfide toxicity (HSDB, 2007) (Section 4.1).

4.3. Structure Activity Relationships

Carbonyl sulfide (S=C=O) is structurally-similar to carbon disulfide (S=C=S) and both are neurotoxic. Carbon disulfide can be metabolized to carbonyl sulfide via the mixed function oxidase system (Sills et al., 2005).

4.4. Other Relevant Information

4.4.1. Species Variability

Results of acute inhalation lethality studies in animals show some species variability.
Mortality incidences for animals exposed to 1000 ppm carbonyl sulfide for 90 minutes were as
follows: 0/6 for guinea pigs, 3/6 for rats, 8/14 for rabbits, and 6/6 for cats (Thiess et al., 1968).

17 18

19

1

2

3

4 5

6 7

8

9

10 11

12

13

4.4.2. Susceptible Populations

20 No information was available on populations especially sensitive to carbonyl sulfide 21 toxicity. However, the extremely steep concentration-response curve implies limited intraspecies 22 variability. The steep curve is evidenced in several studies. No mortality was noted in rats 23 exposed to 943 ppm carbonyl sulfide for 4-hours, and 4/10 rats died at 1090 ppm and 10/10 rats 24 died when exposed to 1210 ppm (DuPont, 1981). In another 4-hour rat study (Monsanto, 1985a), 25 no mortality was noted at 993 ppm; whereas, 4/12 rats died at 1060 ppm, and 11/12 rats died at 1147 ppm. Thiess et al. (1968) observed no mortality in rats exposed to 1000 ppm for 75-min and 26 death of 3/6 rats exposed to 1000 ppm for 90-min. 27

28

29 **4.4.3.** Time Scaling30

The concentration exposure time relationship for many irritant and systemically acting vapors and gases may be described by $C^n x t = k$, where the exponent ranges from 0.8 to 3.5 (ten Berge et al. 1986). In lieu of a definitive data set allowing empirical derivation of the exponent n, temporal scaling was performed, using n = 3 when extrapolating to shorter time points and n = 1 when extrapolating to longer time points using the $C^n x t = k$ equation (NRC 2001).

- 36
- 37 5. DATA ANALYSIS FOR AEGL-1
- 38 39

40

43 44 5.1.

- DATA ANALYSIS FOR AEGL-1 Summary of Human Data Relevant to AEGL-1
- No human data relevant to development of AEGL-1 values were identified.
- 4142 5.2. Summary of Animal Data Relevant to AEGL-1
 - No animal data relevant to development of AEGL-1 values were identified.
- 45 46
- 47 **5.3.** Derivation of AEGL-1
- 48

Data were insufficient for deriving AEGL-1 values for carbonyl sulfide. Therefore,

2 AEGL-1 values are not recommended (Table 9). Also, carbonyl sulfide has poor warning

properties; it may cause serious effects or lethality at concentrations causing no signs or symptoms
 (HSDB, 2007).

5

1

| TABLE 9. AEGL-1 Values for Carbonyl Sulfide | | | | | |
|---|----|----|----|----|--|
| 10-min 30-min 1-h 4-h 8-h | | | | | |
| NR | NR | NR | NR | NR | |

NR: Not Recommended due to insufficient data. The absence of AEGL-1 values does not imply that concentrations
 below AEGL-2 are without effect. Carbonyl sulfide has poor warning properties; it may cause serious effects or
 lethality at concentrations causing no signs or symptoms

9 10

13 14

15

25

11 6. DATA ANALYSIS FOR AEGL-2 12 6.1. Summary of Human Data Relevant to AEGL-2

No human data relevant to development of AEGL-2 values were identified.

6.2. Summary of Animal Data Relevant to AEGL-2 17

Hypoactivity was noted in rats exposed to 804 ppm carbonyl sulfide for 4-hours
(Monsanto, 1985a). Clinical signs (hypothermia, lethargy, head tilt and ataxia) and brain
histopathology were noted in rats exposed to 600 ppm for 6-hours; no clinical signs or brain
lesions were noted in rats exposed to 75, 150, or 300 ppm carbonyl sulfide for 6-hours (Morgan et al., 2004).

24 6.3. Derivation of AEGL-2

26 The NOEL for clinical signs and brain pathology (300 ppm) in rats exposed to carbonyl 27 sulfide for 6-hours (Morgan et al., 2004) will be used as the POD for AEGL-2 values. (Animals 28 exposed to the next highest concentration tested, 600 ppm, exhibited severe clinical signs and brain pathology). Values will be scaled across time using the $C^n x t = k$ equation, where n = 3 when 29 30 extrapolating to shorter time points and n = 1 when extrapolating to longer time points in order to 31 derive values protective of human health (NRC, 2001). The 30-min AEGL-2 value will be 32 adopted as the 10-min AEGL-2 value because of the added uncertainty of extrapolating from the 6-33 hour POD to 10-min. An intraspecies uncertainty factor (UF) of 3 will be applied and is 34 considered sufficient due to the steep concentration-response curve (Section 4.4.2), which implies limited intra-individual variability. An interspecies UF of 3 will also be applied. Although the 35 36 animal data suggest some species variability and the rat is not the most sensitive species [mortality 37 incidences for animals exposed to 1000 ppm carbonyl sulfide for 90 minutes were as follows: 0/6 38 for guinea pigs, 3/6 for rats, 8/14 for rabbits, and 6/6 for cats (Thiess et al., 1968)], use of the full 39 default interspecies UF of 10 would yield AEGL-2 values that are inconsistent with the overall 40 database. [AEGL-2 values derived using a total UF of 30 would be 23 ppm for 10- and 30-min, 18 ppm for 1-hr, 11 ppm for 4-hr, and 7.7 ppm for 8-hr; no treatment-related effects were noted in rats 41 42 exposed to 51 ppm 6-hr/day for 11 days (Monsanto, 1985b), or 75, 150, or 300 ppm 6-hr/day for 4 days (Morgan et al., 2004)]. Therefore, the total adjustment is 10. AEGL-2 values are presented in 43 44 Table 10, and calculations are presented in Appendix A.

- 45
- 46

| TABLE 10. AEGL-2 Values for Carbonyl Sulfide | | | | | | |
|--|------------------------------------|------------------------------------|-----------------------------------|-----------------------------------|--|--|
| 10-min | 10-min 30-min 1-h 4-h 8-h | | | | | |
| 69 ppm (170 mg/m ³) | 69 ppm (170 mg/m ³) | 55 ppm (130 mg/m ³) | 34 ppm (83 mg/m ³) | 23 ppm (56 mg/m ³) | | |

1

3

4

5

6 7

8

9 10

11 12

13

17

19

The proposed AEGL-2 values are considered protective because no treatment-related effects were noted in rats repeatedly exposed to 51 ppm, 6-hr/day for 11 days (Monsanto, 1985b) and 75 or 150 ppm 6-hr/day for 4 days (Morgan et al., 2004).

7. DATA ANALYSIS FOR AEGL-3

7.1. Summary of Human Data Relevant to AEGL-3

No human data relevant to development of AEGL-3 values were identified.

7.2. Summary of Animal Data Relevant to AEGL-3

14 Two well-conducted 4-hr rat acute lethality studies support one another. A BMCL₀₅ of 969 15 ppm and BMC₀₁ of 992 ppm were calculated from a DuPont (1981) study and a BMCL₀₅ of 951.7 16 ppm and BMC₀₁ of 951.9 ppm were calculated from a Monsanto (1985a) study.

18 **7.3.** Derivation of AEGL-3

20 The 4-hour rat BMCL₀₅ (951.9) and BMC₀₁ (951.7) calculated from Monsanto (1985a) are essentially identical and are slightly more conservative than values calculated from the DuPont 21 22 (1981) study. A 4-hr concentration of 952 ppm (rounded BMC values; Monsanto, 1985a) will be 23 used as the point-of-departure (POD) for AEGL-3 values. Values will be scaled across time using 24 the $C^n x t = k$ equation, where n = 3 when extrapolating to shorter time points and n = 1 when 25 extrapolating to longer time points in order to derive values protective of human health (NRC, 2001). The 30-min AEGL-3 value will be adopted as the 10-min AEGL-3 value because of the 26 27 added uncertainty of extrapolating from the 4-hour POD to 10-min. An intraspecies uncertainty 28 factor (UF) of 3 will be applied and is considered sufficient due to the steep concentration-29 response curve (Section 4.4.2), which implies limited intra-individual variability. An interspecies 30 UF of 3 will also be applied. Although the animal data suggest some species variability and the rat 31 is not the most sensitive species [mortality incidences for animals exposed to 1000 ppm carbonyl 32 sulfide for 90 minutes were as follows: 0/6 for guinea pigs, 3/6 for rats, 8/14 for rabbits, and 6/6 33 for cats (Thiess et al., 1968)], use of the full default interspecies UF of 10 would yield AEGL-3 34 values that are inconsistent with the overall database. [AEGL-3 values derived using a total UF of 35 30 would be 63 ppm for 10- and 30-min, 50 ppm for 1-hr, 32 ppm for 4-hr, and 16 ppm for 8-hr; no treatment-related effects were noted in rats exposed to 51 ppm 6-hr/day for 11 days (Monsanto, 36 37 1985b), or 75, 150, or 300 ppm 6-hr/day for 4 days (Morgan et al., 2004). No mortality or clinical 38 signs were present in rats exposed to 200, 300, and 400 ppm 6 hr/day, 5 days/week for 12-weeks; 39 however, significant decreases in brain cholinesterase activity were noted at all three 40 concentrations (Morgan et al., 2004)]. Therefore, the total adjustment is 10. AEGL-3 values are 41 presented in Table 11, and calculations are presented in Appendix A.

| TABLE 11. AEGL-3 Values for Carbonyl Sulfide | | | | | |
|--|------------------------|------------------------|------------------------|------------------------|--|
| 10-min 30-min 1-h 4-h 8-h | | | | | |
| 190 ppm | 190 ppm | 150 ppm | 95 ppm | 48 ppm | |
| (470 mg/m^3) | (470 mg/m^3) | (370 mg/m^3) | (230 mg/m^3) | (120 mg/m^3) | |

The proposed AEGL-3 values are considered protective because no treatment-related effects were noted in rats repeatedly exposed to 75, 150, or 300 ppm 6-hr/day for 4 days (Morgan 4 et al., 2004). No treatment-related clinical signs of FOB effects were noted in male and female 5 rats exposed to 300 ppm, 6 hr/day, 5 days/week for 12 exposures in a two-week period; brain 6 lesions were noted only in 1/5 females in this study (Morgan et al., 2004). No mortality or clinical 7 signs were present in rats exposed to 200, 300, or 400 ppm 6 hr/day, 5 days/week for 12-weeks; 8 however, significant decreases in brain cholinesterase activity were noted at all three 9 concentrations (Morgan et al., 2004).

10

13

11 8. **SUMMARY OF AEGLS**

12 8.1. **AEGL Values and Toxicity Endpoints**

14 AEGL values are summarized in Table 12. AEGL-1 values are not recommended due to 15 insufficient data and poor warning properties. AEGL-2 values were based on a NOEL for clinical signs of neurotoxicity and brain lesions in rats (Morgan et al., 2004), and AEGL-3 values were 16 17 based on a 4-hr rat BMCL₀₅/BMC₀₁ value (Monsanto, 1985a).

18

| TABLE 12. Summary of AEGL Values | | | | | | |
|----------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------------|------------------------------------|--|
| Classification | | | Exposure Duration | ı | | |
| Classification | 4-h | 8-h | | | | |
| AEGL-1 (Nondisabling) | NR | NR | NR | NR | NR | |
| AEGL-2 (Disabling) | 69 ppm (170 mg/m ³) | 69 ppm (170 mg/m ³) | 55 ppm (130 mg/m ³) | 34 ppm (83 mg/m ³) | 23 ppm (56 mg/m ³) | |
| AEGL-3 (Lethal) | 190 ppm (470 mg/m ³) | 190 ppm (470 mg/m ³) | 150 ppm (370 mg/m ³) | 95 ppm (230 mg/m ³) | 48 ppm (120 mg/m ³) | |

NR: Not Recommended due to insufficient data. The absence of AEGL-1 values does not imply that concentrations 19 20 below AEGL-2 are without effect. Carbonyl sulfide has poor warning properties; it may cause serious effects or 21 lethality at concentrations causing no signs or symptoms

8.2. **Comparison with Other Standards and Guidelines**

22

27

28 29

30

31 32

33 34

35 36 37

38

There are no other extant standards or guidelines for carbonyl sulfide.

8.3. **Data Adequacy and Research Needs**

There are no human data, and high-quality animal data are limited to rats. Additional acute inhalation toxicity studies in other animal species would be helpful.

9. REFERENCES

Bartholomaeus, A. R. and Haritos, V. S. 2005. Review of the toxicology of carbonyl sulfide, a new grain fumigant. Food and Chemical Toxicology. 43: 1687-1701.

Chengelis, C. C. and Neal, R. A. 1979. Hepatic carbonyl sulfide metabolism. Biochemical and Biophysical Research Communications. 90: 993-999.

- Chengelis, C. C. and Neal, R. A. 1980. Studies of carbonyl sulfide toxicity: metabolism by carbonic anhydrase. Toxicol. Appl. Pharmacol. 55: 198-202.
- DuPont. 1981. Initial submission: acute inhalation toxicity of carbon oxide sulfide in rats with cover letter dated 080992. E. I. DuPont de Nemours and Company, Haskell Laboratory for Toxicology and Industrial Medicine, Newark, Delaware. OTS0571009.
- HSDB (Hazardous Substances Data Bank). 2007. Carbonyl Sulfide. Online data base, National Library of Medicine: http://toxnet.nlm.nih.gov/cgi-bin/sis.
- Hugod, C., and Astrup, P. 1980. Exposure of rabbits to carbon monoxide and other gas phase constituents of tobacco smoke. Munch. Med. Wschr. 122: S18-S24.
- Hugod, C. 1981. Myocardial morphology in rabbits exposed to various gas-phase constituents of tobacco smoke. An ultrastructural study. Atherosclerosis. 40: 181-190.
- Kamstrup, O., and Hugod, C. 1979. Exposure of rabbits to 50 ppm carbonyl sulfide. Int. Arch. Occup. Environ. Health. 44: 109-116.
- Kilburn, K. H. and Warshaw, R. H. 1995. Hydrogen sulfide and reduced-sulfur gases adversely affect neurophysiological functions. Toxicol. Ind. Health. 11:185-197.
- Monsanto. 1985a. Initial submission: acute toxicity of carbon oxysulfide administered by inhalation to male and female Sprague-Dawley rats (final report) with attachments and letter dated 112791. Monsanto Company, Environmental Health Laboratory, St. Louis, Mo. OTS0534820.
- Monsanto. 1985b. Initial submission: two-week study with carbonyl sulfide administered by inhalation to rats with cover letter dated 052892. Monsanto Company, Environmental Health Laboratory, St. Louis, Mo. OTS0540051.
- Morgan, D. L., Little, P. B., Herr, D. W., et al. 2004. Neurotoxicity of carbonyl sulfide in F344 rats following inhalation exposure for up to 12 weeks. Toxicology and Applied Pharmacology. 200: 131-145.
- NRC (National Research Council). 2001. Standing Operating Procedures for Acute Exposure Guideline Levels for Selected Airborne Chemicals. The National Academies Press, Washington, DC.
- Nutt, A. W., Benson, J. M., Barr, E. B., et al. 1996. Acute inhalation toxicity of carbonyl sulfide. Fund. Appl. Toxicol. Supplement. 30:18. (abstract)
- Reyna, M. S. and Ribelin, W. E. 1987. One-generation reproduction studies of male albino rats, female albino rats, and previously exposed male Sprague-Dawley rats to carbonyl sulfide by inhalation. Monsanto Technical Laboratory, submitted by E. I. DuPont de Nemours & Co. OTS 0555041.
- Sills, R. C., Harry, G. J., Valentine, W. M., and Morgan, D. L. 2005. Interdisciplinary neurotoxicity inhalation studies: carbon disulfide and carbonyl sulfide research in F344 rats. Toxicol. Appl. Pharmacol. 207: S2245-S250.
- ten Berge, W.F., Zwart, A., Appelman, L.M. 1986. Concentration-time mortality response relationship of irritant and systemically acting vapours and gases. J. Hazard. Materials: 13: 301-309.
- Thiess, A. M., Hey, W., Hofmann, H. T., and Oettel, H. 1968. The toxicity of carbon oxysulfide- illustrated by a case of fatal poisoning. Archiv. Fur Toxikologie. 23: 253-263.
- U. S. EPA. 1992. Reference Guide to Odor Thresholds for Hazardous Air Pollutants Listed in the Clean Air Act Amendments of 1990. Air Risk Support Center, U. S. Environmental Protection Agency. Page 2-10. EPA600/R-92-047. March, 1992.

APPENDIX A: Derivation of AEGL Values

Derivation of AEGL-1 AEGL-1 values are not recommended due to insufficient data. The absence of AEGL-1 values does not imply that concentrations below AEGL-2 are without effect. Carbonyl sulfide has poor warning properties; it may cause serious effects or lethality at concentrations causing no signs or symptoms

| 1 | | Derivation of AEGL-2 | | | | | | |
|--|--|---|--|--|--|--|--|--|
| 2 3 4 5 | Key Study: Morgan et al., 2004 Toxicity endpoint: 300 ppm for 6-hr: NOEL for clinical signs and brain pathology in rats | | | | | | | |
| 6 7 8 9 | Time scaling: Values were extrapolated using the relationship $C^n x t = k$ (ten Berge et al.198) where n = 3 when extrapolating to shorter time points and n = 1 when extrapolating to longer time points in order to derive values protective of human health (NRC, 2001). The 30-min values | | | | | | | |
| 10 11 12 13 14 | 10 11 <u>30-min, 1-hr, 4-hr</u> 12 $C^3 x t = k$ 13 (300 ppm) ³ x 6 hr = 162,000,000 ppm ³ ·hr | | | | | | | |
| 14 15 16 17 | $\frac{8-hr}{(300 \text{ ppm})^1 \text{ x } 6 \text{ hr}} = 1800 \text{ ppm} \cdot \text{hr}$ | | | | | | | |
| 18 19 20 | Uncertainty factors: | 3 for interspecies variability.3 for intraspecies variability. | | | | | | |
| 21 22 23 | 10-minute AEGL-2: | 69 ppm (30-min value adopted as 10-min value) | | | | | | |
| 23 24 25 26 27 28 | 30-minute AEGL-2: | $C^{3} \ge 0.5 \text{ hr} = 162,000,000 \text{ ppm}^{3} \cdot \text{hr}$ $C^{3} = 324,000,000 \text{ ppm}$ C = 687 ppm AEGL-2 = 687 ppm ÷ 10 = 69 ppm | | | | | | |
| 29 30 31 32 33 34 35 36 37 | 1-hour AEGL-2: | $C^{3} x 1 hr = 162,000,000 ppm^{3} hr$ $C^{3} = 162,000,000 ppm$ C = 545 ppm AEGL-2 = 545 ppm $\div 10 = 55 ppm$ | | | | | | |
| | 4-hour AEGL-2: | $C^{3} x 4 hr = 162,000,000 ppm^{3} hr$ $C^{3} = 40,500,000 ppm$ C = 343 ppm AEGL-2 = 343 ppm ÷ 10 = 34 ppm | | | | | | |
| 38 39 40 41 42 | 8-hour AEGL-2: | $C^{1} x 8 hr = 1800 ppm hr$ C = 225 ppm $AEGL-2 = 225 ppm \div 10 = 23 ppm$ | | | | | | |

| 1 | | Derivation of AEGL-3 | | | | | | |
|----------------------------------|--|--|--|--|--|--|--|--|
| 2 3 4 5 6 | Key Study: Monsanto, 1985a Toxicity endpoint: 4-hr rat $BMCL_{05}$ and BMC_{01} of 952 ppm ($BMCL_{05}$ and BMC_{01} values are equivalent) | | | | | | | |
| 7 8 9 10 | Time scaling: Values were extrapolated using the relationship $C^n x t = k$ (ten Berge et al.1986), where $n = 3$ when extrapolating to shorter time points and $n = 1$ when extrapolating to longer time points in order to derive values protective of human health (NRC, 2001). 30-min value was adopted as the 10-min value. | | | | | | | |
| 11 12 13 14 | $\overline{C^3 x t} = k$ | | | | | | | |
| 15 16 17 18 | $\frac{8-hr}{(952 \text{ ppm})^1} \times 4 \text{ hr} = 3$ | | | | | | | |
| 19 20 21 | Uncertainty factors: | 3 for interspecies variability.3 for intraspecies variability. | | | | | | |
| 22 23 24 | 10-minute AEGL-3: | 190 ppm (30-min value adopted as 10-min value) | | | | | | |
| 24 25 26 27 28 29 | 30-minute AEGL-3: | $C^{3} \ge 0.5 \text{ hr} = 3,451,205,632 \text{ ppm}^{3} \cdot \text{hr}$ $C^{3} = 6,902,411,264 \text{ ppm}$ C = 1904 ppm AEGL-3 = 1904 ppm ÷ 10 = 190 ppm | | | | | | |
| 29 30 31 32 33 34 | 1-hour AEGL-3: | $C^{3} x 1 hr = 3,451,205,632 ppm^{3} hr$ $C^{3} = 3,451,205,632 ppm$ C = 1511 ppm AEGL-3 = 1511 ppm ÷ 10 = 150 ppm | | | | | | |
| 35 36 37 | 4-hour AEGL-3: | C = 952 ppm AEGL-3 = 952 ppm ÷ 10 = 95 ppm | | | | | | |
| 38 39 40 41 | 8-hour AEGL-3: | $C^{1} x 8 hr = 3808 ppm hr$ C = 476 ppm AEGL-3 = 476 ppm ÷ 10 = 48 ppm | | | | | | |

APPENDIX B: Derivation Summary for Carbonyl Sulfide AEGLs

AEGL-1 Values for Carbonyl Sulfide

| 10-min | 30-min | 1-h | 4-h | 8-h | | |
|--|-------------------------|-----|-----|-----|--|--|
| NR | NR | NR | NR | NR | | |
| Key Reference: | | | | | | |
| Test Species/Strain/ | Number: | | | | | |
| Exposure Route/Cor | ncentrations/Durations: | | | | | |
| Effects: | | | | | | |
| | | | | | | |
| Endpoint/Concentra | tion/Rationale: | | | | | |
| Uncertaint | y Factors/Rationale: | | | | | |
| Modifying Factor: N | IA | | | | | |
| Animal to Human D | osimetric Adjustment: | | | | | |
| Time Scaling: | | | | | | |
| Data Adequacy: NR: Not Recommended due to insufficient data. The absence of AEGL-1 values does not imply that concentrations below AEGL-2 are without effect. Carbonyl sulfide has poor warning properties; it may cause serious effects or lethality at concentrations causing no signs or symptoms | | | | | | |

| 10-min | 30-min | 1-h | 4-h | 8-h | | | |
|--|--|-------------------------------|---------------------------|------------------------|--|--|--|
| 69 ppm | 69 ppm | 55 ppm | 34 ppm | 23 ppm | | | |
| | | | | | | | |
| | Key Reference: Morgan, D. L., Little, P. B., Herr, D. W., et al. 2004. Neurotoxicity of carbonyl sulfide in F344 rats following inhalation exposure for up to 12 weeks. Toxicology and Applied Pharmacology. | | | | | | |
| | 200: 131-145. | | | | | | |
| Test Species/Strain/ | Number: rat/F344/5 mal | les/concentration | | | | | |
| Exposure Route/Cor | centrations/Durations: I | Inhalation/0, 75, 150, 300 |), 600 ppm/6-hrs | | | | |
| Effects: | | | | | | | |
| No mortality at any | concentration. | | | | | | |
| <u>75, 150 ppm</u> : NOEL | , for all effects | | | | | | |
| 300 ppm: NOEL for | r clinical signs and brain | a pathology | | | | | |
| | C | 1 05 | | | | | |
| | | head tilt, hypothermia, an | | | | | |
| | | us, internal capsule, and | thalamus. Vacuolation | of the cerebellar | | | |
| | tter and fifth cranial nerv | | | | | | |
| | | et-level for clinical signs a | and brain pathology/300 |) ppm | | | |
| Uncertainty Factors/ | Rationale: | | | | | | |
| Intraspecies: 3 | | , .· | 1 . 1 . 1. | 1 1 | | | |
| | | eep concentration-response | | | | | |
| | | arve is evidenced in sever | | | | | |
| | | de for 4-hours, and 4/10 | | | | | |
| | | nt, 1981). In another 4-h | | | | | |
| | | 12 rats died at 1060 ppm, | | | | | |
| | | rats exposed to 1000 ppr | m for 75-min and death | of 3/6 rats exposed to | | | |
| | for 90-min. | | | | | | |
| Interspecies: 3 | | | | | | | |
| | | some species variability a | | | | | |
| | | exposed to 1000 ppm carb | | | | | |
| | | 14 for rabbits, and 6/6 for | | | | | |
| | | d yield AEGL-2 values th | | | | | |
| | | tal UF of 30 would be 23 | | | | | |
| | | -hr; no treatment-related | | | | | |
| 5 | or 11 days (Monsanto, 19 | 985b), or 75, 150, or 300 | ppm 6-hr/day for 4 day | s (Morgan et al., | | | |
| 2004)]. | | | | | | | |
| Modifying Factor: N | Modifying Factor: NA | | | | | | |
| Animal to Human Dosimetric Adjustment: | | | | | | | |
| | | = 3 when extrapolating t | to shorter time points an | d n = 1 when | | | |
| | | points in order to derive | | | | | |
| 200 | 1). 30-min value was ad | lopted as the 10-min valu | e because the point-of- | departure is 6-hr. | | | |
| | | lues are considered prote | | | | | |
| | 1 | dly exposed to 51 ppm, 6 | 5 | onsanto, 1985b) and | | | |
| 75 | or 150 ppm 6-hr/day fc | or 4 days (Morgan et al., 2 | 2004). | | | | |

AEGL-2 Values for Carbonyl Sulfide


AEGL-3 Values for Carbonyl Sulfide

| 10-min | 30-min | 1-h | 4-h | 8-h | | | |
|---|---|--|---|---|--|--|--|
| 190 ppm | 190 ppm | 150 ppm | 95 ppm | 48 ppm | | | |
| Key Reference: Monsanto. 1985a. | Key Reference: | | | | | | |
| Test Species/Strain/ | Number: Rat/Sprague-Da | awlev/six/sex/concentrat | tion | | | | |
| | Test Species/Strain/Number: Rat/Sprague-Dawley/six/sex/concentration Exposure Route/Concentrations/Durations: Inhalation/ 4-hrs | | | | | | |
| Effects: | | | | | | | |
| | <u>lortality</u> | | | | | | |
| 0 ppm | 0/12 | | | | | | |
| 804 ppm | 0/12 | | | | | | |
| 993 ppm | 0/12 | | | | | | |
| 1062 ppm | 4/12 | | | | | | |
| 1096 ppm | 8/12 | | | | | | |
| 1147 ppm | 1/12 | | | | | | |
| 1189 ppm | 11/12 | | | | | | |
| | | | | | | | |
| LC ₅₀ : | 1082 ppm | | | | | | |
| BMC ₀₁ : | 951.7 ppm | | | | | | |
| BMCL ₀₅ : | 951.9 ppm | | | | | | |
| Endpoint/Concentra | | | 1.1.1.1. | | | | |
| | BMCL ₀₅ of 952 ppm, con | nsidered a threshold for | lethality | | | | |
| Uncertainty Factors | Rationale: | | | | | | |
| individual exposed to when expor- was noted al. (1968) 1000 ppm Interspecies: 3 Although t [mortality 0/6 for gui default inte [AEGL-3 32 ppm for 6-hr/day fo 2004). No | d sufficient due to the ste variability. The steep cu 943 ppm carbonyl sulfic osed to 1210 ppm (DuPor at 993 ppm; whereas, 4/1 observed no mortality in for 90-min. the animal data suggest se incidences for animals en nea pigs, 3/6 for rats, 8/1 erspecies UF of 10 would values derived using a to r 4-hr, and 16 ppm for 8- or 11 days (Monsanto, 19 o mortality or clinical sign for 12-weeks (Morgan e | arve is evidenced in seve de for 4-hours, and 4/10 ht, 1981). In another 4-h 12 rats died at 1060 ppm rats exposed to 1000 pp ome species variability a xposed to 1000 ppm carl 4 for rabbits, and 6/6 for d yield AEGL-3 values th tal UF of 30 would be 62 hr; no treatment-related 085b), or 75, 150, or 300 ns were present in rats ex | ral studies. No mortalit rats died at 1090 ppm an iour rat study (Monsanto , and 11/12 rats died at m for 75-min and death and the rat is not the mor ponyl sulfide for 90 min r cats (Thiess et al., 196 hat are inconsistent with 3 ppm for 10- and 30-mi effects were noted in rat ppm 6-hr/day for 4 day | y was noted in rats nd 10/10 rats died o, 1985a), no mortality 1147 ppm. Thiess et of 3/6 rats exposed to st sensitive species sutes were as follows: 8)], use of the full n the overall database. in, 50 ppm for 1-hr, ts exposed to 51 ppm s (Morgan et al., | | | |
| Modifying Factor: N | JA | | | | | | |
| | Oosimetric Adjustment: | | | | | | |
| Time Scaling: C ⁿ x extr | t = k equation, where n apolating to longer time 1). 30-min value was ad | points in order to derive | values protective of hun | man health (NRC, | | | |

Data Adequacy: The proposed AEGL-3 values are considered protective because no treatment-related effects were noted in rats repeatedly exposed to 75, 150, or 300 ppm 6-hr/day for 4 days (Morgan et al., 2004). No treatment-related clinical signs of FOB effects were noted in male and female rats exposed to 300 ppm, 6 hr/day, 5 days/week for 12 exposures in a two-week period; brain lesions were noted only in 1/5 females in this study (Morgan et al., 2004). No mortality or clinical signs were present in rats exposed to 200, 300, and 400 ppm 6 hr/day, 5 days/week for 12-weeks; however, significant decreases in brain cholinesterase activity were noted at all three concentrations (Morgan et al., 2004).

APPENDIX C: Category Plot for Carbonyl Sulfide





APPENDIX D: Benchmark Dose Calculations for Carbonyl Sulfide

| | File: C:\BMDS\CARBONYL_SULFIDE_MONSANTO.(d) otting File: C:\BMDS\CARBONYL_SULFIDE_MONSANTO.plt Fri Sep 14 09:47:57 2007 |
|-----------------------------|---|
| BMDS MODE | L RUN |
| The form of t | ne probability function is: |
| P[response] = + (1-B) | Background ackground) * CumNorm(Intercept+Slope*Log(Dose)), |
| where CumNo | rm(.) is the cumulative normal distribution function |
| Independent v | iable = COLUMN3 ariable = COLUMN1 er is not restricted |
| Total number Maximum nur | of observations = 7 of records with missing values = 0 nber of iterations = 250 tion Convergence has been set to: 1e-008 |
| | wergence has been set to: 1e-008 |
| User has chose | en the log transformed model |
| bac int | ult Initial (and Specified) Parameter Values kground = 0 ercept = -61.2273 slope = 8.79468 |
| Asympto | tic Correlation Matrix of Parameter Estimates |
| have | e model parameter(s) -background -slope been estimated at a boundary point, or have been specified by the us o not appear in the correlation matrix) |
| intercep | ot |
| ntercept | 1 |
| | Parameter Estimates |
| Variable | Estimate Std. Err. |

INTERIM: 05-2008/ Page 36 of 38

| 1 2 3 | background intercept slope | 0 -125.774 18 | NA 0.200664 NA | | | | |
|-----------------------|--|---------------------------------------|---------------------------|--------------|--|--|--|
| 4 5 6 7 8 | NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error. | | | | | | |
| 9 | | | T 11 | | | | |
| 10 11 | Ar | alysis of Devia | nce l'able | | | | |
| 12 | Model Lo | g(likelihood) D | eviance Test DI | F P-value | | | |
| 13 | Full model | -22.1604 | | 1 Vulue | | | |
| 14 | Fitted model | | 2.64201 6 | 0.8522 | | | |
| 15 | Reduced model | -56.6912 | 69.0616 6 | <.0001 | | | |
| 16 | | | | | | | |
| 17 | AIC: | 48.9628 | | | | | |
| 18 | | | | | | | |
| 19 20 | C | 1 f. F.'. | | | | | |
| 20 21 | G00 | dness of Fit | | | | | |
| 21 | | | Scaled | | | | |
| 22 | Dose Est. P | rob. Expected | | ize Residual | | | |
| 24 | | | | | | | |
| 25 | 1189.0000 0.9 | 9536 11.44 | 4 11 1 | -0.6092 | | | |
| 26 | 1147.0000 0.8 | 3494 10.19 | 3 11 1 | 0.6514 | | | |
| 27 | 1096.0000 0.5 | 5852 7.022 | 2 8 12 | 0.5728 | | | |
| 28 | | 3624 4.349 | | | | | |
| 29 | | 592 0.711 | 0 12 | | | | |
| 30 | | 000 0.000 | | | | | |
| 31 | 0.0000 0.00 | 00 0.000 | 0 12 | 0 | | | |
| 32 | | 1.02 DE = 6 | \mathbf{D} we have -0 | 0266 | | | |
| 33 34 | Chi-square = | 1.92 DF = 0 | P-value – 0. | 9200 | | | |
| 35 | | | | | | | |
| 36 | Benchmark Dos | se Computation | | | | | |
| 37 | | · · · · · · · · · · · · · · · · · · · | | | | | |
| 38 | Specified effect = | 0.05 | | | | | |
| 39 | | | | | | | |
| 40 | Risk Type = | Extra risk | | | | | |
| 41 42 | Confidence level | = 0.95 | | | | | |
| 43 44 | BMD = | 988.398 | | | | | |
| 45 46 | DMDI – | 951.913 | | | | | |
| 40 | DMDL - | 731.713 | | | | | |

| | Probit Model \$Revision: 2.1 \$ \$Date: 2000/02/26 03:38:53 \$ Input Data File: C:\BMDS\CARBONYL_SULFIDE_MONSANTO.(d) Gnuplot Plotting File: C:\BMDS\CARBONYL_SULFIDE_MONSANTO.plt Fri Sep 14 09:54:53 2007 |
|---|---|
| 3 | MDS MODEL RUN |
| , | The form of the probability function is: |
| | P[response] = Background + (1-Background) * CumNorm(Intercept+Slope*Log(Dose)), |
| | where CumNorm(.) is the cumulative normal distribution function |
| | Dependent variable = COLUMN3 Independent variable = COLUMN1 Slope parameter is not restricted |
| | Total number of observations = 7 Total number of records with missing values = 0 Maximum number of iterations = 250 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008 |
| - | User has chosen the log transformed model |
| | Default Initial (and Specified) Parameter Values background = 0 intercept = -61.2273 slope = 8.79468 |
| | Asymptotic Correlation Matrix of Parameter Estimates |
| | (*** The model parameter(s) -background -slope have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix) |
| | intercept |
| r | ntercept 1 |

| 1 2 | Parameter Estimates |
|----------|--|
| 3 4 | Variable Estimate Std. Err. |
| 5 | |
| 6 | background 0 NA intercept -125.774 0.200664 |
| 7 | slope 18 NA |
| 8 | |
| 9 | NA - Indicates that this parameter has hit a bound |
| 10 | implied by some inequality constraint and thus |
| 11 | has no standard error. |
| 12 | |
| 13 | Analysis of Deviance Table |
| 14 | |
| 15 | Model Log(likelihood) Deviance Test DF P-value |
| 16 | Full model -22.1604 |
| 17 | Fitted model -23.4814 2.64201 6 0.8522 |
| 18 | Reduced model -56.6912 69.0616 6 <.0001 |
| 19 20 | AIC: 48.9628 |
| 20 21 | AIC: 48.9028 |
| 21 | Goodness of Fit |
| 22 | |
| 24 | Scaled |
| 25 | Dose EstProb. Expected Observed Size Residual |
| 26 | |
| 27 | 1189.0000 0.9536 11.444 11 12 -0.6092 |
| 28 | 1147.0000 0.8494 10.193 11 12 0.6514 |
| 29 | 1096.0000 0.5852 7.022 8 12 0.5728 |
| 30 | 1062.0000 0.3624 4.349 4 12 -0.2096 |
| | 993.0000 0.0592 0.711 0 12 -0.8692 |
| 32 | 804.0000 0.0000 0.000 0 12 -0.0007035 |
| 33 | 0.0000 0.0000 0.000 0 12 0 |
| 34 | |
| 35 | Chi-square = 1.92 DF = 6 P-value = 0.9266 |
| 36 37 | |
| 38 | Benchmark Dose Computation |
| 39 | Benefilmark Dose Computation |
| 40 | Specified effect = 0.01 |
| 41 | |
| 42 | Risk Type = Extra risk |
| 43 | |
| 44 | $Confidence \ level = 0.95$ |
| 45 | |
| 46 | BMD = 951.676 |
| 47 | |
| 48 | BMDL = 906.266 |
| 49 | |